Rapamycin (Sirolimus)

For research use only.

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

1106 publications

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Rapamycin (Sirolimus) has been cited by 1106 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NF7Ob2tEgXSxdH;4bYMhSXO|YYm= MWmxNEBvVQ>? M4PIO|czKGh? NFrJbIdFVVOR MV3Qc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= MnO0NlQ6ODB6N{O=
HT-29 MWPDfZRwfG:6aXOgRZN{[Xl? MWmxNEBvVQ>? NFGxTI44OiCq NVzPdWRjTE2VTx?= NXTNSZFsWG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NWTvPY82OjR7MEC4O|M>
HT-29 M2jOSGN6fG:2b4jpZ{BCe3OjeR?= NUXKR4JLOTBibl2= MkjBO|IhcA>? MXzEUXNQ NH;2b2pRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MnL5NlQ6ODB6N{O=
PC3 NYTtW4p2U2mwYYPlJGF{e2G7 M1\YZlExOCCwTR?= NWnzOXBJOSCq Mnr3SG1UVw>? MVfQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= M4XVTlIyQTd6Nkiz
PC3 MoXaT4lv[XOnIFHzd4F6 NV3CVVN[OTByIH7N MoL1NUBp MojDSG1UVw>? M1XwTWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M2\CSlIyQTd6Nkiz
PC3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G4PFEvPSEQvF2= Mk\NNUBp NV31Tmt6TE2VTx?= M1flTWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NUPwS5pROjF7N{i2PFM>
HEK293 MkL1SpVv[3Srb36gRZN{[Xl? NE\KO2UyODBibl2= Mo[5PEBp MnHySG1UVw>? MYfJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? NYfG[oYzOjF3M{mzNFE>
BT-20 NEfIZlFMcW6jc3WgRZN{[Xl? NHLQU4ozOCEQvF2= M{DvZ2ROW09? NFH1bIpFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= NEGwR28zOTN3M{W1NS=>
U937 NEfJbIdCdnSrYnHjeIVzcWGuIFHzd4F6 NGHWSHU2OCEQvF2= NGjZUHI1QCCq Mmi2SG1UVw>? MmLxTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| M4rWcFIyOTR{MUC2
U937 MmTIRY51cWKjY4TldolidCCDc4PhfS=> NX;mfWk1PTBizszN NELhfFY1QCCq MlqxSG1UVw>? M12yZmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? M1H0OlIyOTR{MUC2
U937 MlzyRY51cWKjY4TldolidCCDc4PhfS=> M2HBZlUxKM7:TR?= MXy0PEBp MWDEUXNQ M2\qemRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ NHr2[3EzOTF2MkGwOi=>
MCF-7 M4jYNmF2fG:yaHHnfUBCe3OjeR?= NHzMVGM{OCCwTR?= M2\DTVQhcA>? NInUcGhFVVOR MVjJcoR2[2W|IHH1eI9xcGGpeR?= NYjQUYdGOjByMkixN|Q>
U87MG M3TNemtqdmG|ZTDBd5NigQ>? MnjhNUDPxE1? Mk[5OkBp NWr5c5N5TE2VTx?= MlH3VI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? MUOxPVg1QDRyNB?=
U87MG MmP0T4lv[XOnIFHzd4F6 MWWxJO69VQ>? NEPle5I3KGh? Mn3XSG1UVw>? NWi0U2xSWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> NVHaWHFtOTl6NEi0NFQ>
U87MG NHS4d3FMcW6jc3WgRZN{[Xl? NV3zWZpCOSEQvF2= MXG2JIg> NWDqOFhnTE2VTx?= NGfwXoFFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= M{O3SlE6QDR6NEC0
U87MG NV3wc5lRU2mwYYPlJGF{e2G7 NHrDZ|YyKM7:TR?= M3XxWlYhcA>? NEPnPHlFVVOR NVvac3M4TG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w MoP1NVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb NGf0bW5CfXSxcHjh[5khSXO|YYm= M{nMOVAvOiEQvF2= NVvKW5RKOjRiaB?= M17oZ2ROW09? NG\NUWdKdmS3Y3XzJIF2fG:yaHHnfS=> NVvxW5BNOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 MUjBeZRweGijZ4mgRZN{[Xl? NWPQZYU3OC5{IN88US=> NInEdXAzPCCq MluwSG1UVw>? NV60WWZYUW6mdXPld{BifXSxcHjh[5k> NWnSco1yOTh|OUG5OFk>
H4 NUHPV3VzTnWwY4Tpc44hSXO|YYm= MnjBNE4zKM7:TR?= MW[yOEBp NYTNZYVNTE2VTx?= MVHJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NFz1S4UyQDB{NEW4OC=>
HeLa M{X5ZmZ2dmO2aX;uJGF{e2G7 Mk\SNVAxKG6P MlPON|YhcA>? MoiySG1UVw>? NHr2bo5KdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NUnJSmx{OTd3NkOzPFU>
HeLa NYTZN5dRTnWwY4Tpc44hSXO|YYm= NFLocmMyODBibl2= NXPGTmVjOzZiaB?= NEThZlZFVVOR NYW0bFU6UW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MWCxO|U3OzN6NR?=
HeLa NXjWVnVnTnWwY4Tpc44hSXO|YYm= M3;hOFExOCCwTR?= MV2zOkBp MleySG1UVw>? M1XFd2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> MXqxO|U3OzN6NR?=
SYF NEfRfYRHfW6ldHnvckBCe3OjeR?= M1rZUlExOCCwTR?= M16xdVI1KGh? M1;rbGROW09? NHjB[|hKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NX7FdYdrOTd3NkOzPFU>
SYF MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLnNVAxKG6P MlnJNlQhcA>? NXL2OIZRTE2VTx?= NVHNe5hZUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> M3KyVFE4PTZ|M{i1
HEK293T MWTBcpRqfmm{YXygRZN{[Xl? MmHnNUBvVQ>? MUS0JIQ> NVPT[nJwTE2VTx?= M3HCTGlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N M1XzOlE4PDh3NUCx
HEK293T MVvBcpRqfmm{YXygRZN{[Xl? MVSxJI5O MoXLOEBl NILkeopFVVOR NFXHXI1KdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> M3vRbVE4PDh3NUCx
PBMC MkTTSpVv[3Srb36gRZN{[Xl? NGDxb4QyKG6P NV;lTYlTOTRiZB?= M2[xcWROW09? NFr4W4pT\WS3Y3XzJGNEWjViZHXud4l1gQ>? NHToZosyPzR6NUWwNS=>
PBMC MWjGeY5kfGmxbjDBd5NigQ>? NInjVFYyKG6P MYCxOEBl NVLuToxlTE2VTx?= M4frPWRw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 NH\OblkyPzR6NUWwNS=>
HEK293 cells MW\LbY5ie2ViQYPzZZk> MXi1NEBvVQ>? M{TQUFQ2KG2rbh?= NUTpdmJzTE2VTx?= NHXDdYNKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P M1izc|E4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M{PkV2Z2dmO2aX;uJGF{e2G7 NELVO44yODBibl2= NV\5Oo93PCCq MlvvSG1UVw>? NF[wdGNKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? M3;3PFE4OTJ6Mk[y
Human mixed lymphocyte MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPCeGw2KG6P M3fmeGROW09? MoLuTWM2OD1zLk[gcm0v MVqxOlE5PTh4NR?=
Lewis rat lymph node cells NV7tbo1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\s[YNNPSEQvF2= MlnhSG1UVw>? NEPNUFFKSzVyPUKuOkDPxE1? MofZNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTuNVAhdk1? MWC3NkBp MU\EUXNQ M3:3VmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= MoTWNVAxOjF7NEi=
MRK-nu-1 NUT3c2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwOES1JJBO MlnnV2FPT0WU
OCUB-M M4e4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjDTWM2OD13LkK0JJBO MVjTRW5ITVJ?
SF539 NE\4TVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[1TWM2OD1zMT62JJBO NWDJUWRVW0GQR1XS
ES4 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXWNVZKSzVyPUKxMlUheE1? MXvTRW5ITVJ?
RL95-2 M3\xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFyNzDwUS=> M1nsXnNCVkeHUh?=
LC-2-ad NEC3TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW1TWM2OD12MkOgdG0> NYnVS41RW0GQR1XS
Daudi M1rkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPwPVlKSzVyPUSzOEBxVQ>? MlXEV2FPT0WU
NTERA-S-cl-D1 NUDuWpl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\LTWM2OD12NEOgdG0> M172SnNCVkeHUh?=
OS-RC-2 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PjSGlEPTB;NkWyJJBO NGS4PWFUSU6JRWK=
VA-ES-BJ MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC2WXFKSzVyPUeyN{BxVQ>? M2rFSXNCVkeHUh?=
GR-ST Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTh2NjDwUS=> NVXB[W1iW0GQR1XS
SW872 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPxTWM2OD16NE[gdG0> M2rqcnNCVkeHUh?=
NOS-1 M4fRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmxOIlCUUN3ME24O|EheE1? NUi5Z4NOW0GQR1XS
MC116 NHzhUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0dXNPUUN3ME25PFUheE1? NWToN45iW0GQR1XS
NCI-H1355 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XRWGlEPTB;MT6wNUBvVQ>? NGDaSmlUSU6JRWK=
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HT[GlEPTB;MT6xPUBvVQ>? MnSzV2FPT0WU
TE-15 M3\LPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jq[mlEPTB;MT6zOkBvVQ>? M3q3dHNCVkeHUh?=
Ramos-2G6-4C10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfxelZKSzVyPUGuOFYhdk1? M1i0eHNCVkeHUh?=
KU812 NFLUc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf0TWM2OD1{LkCxJI5O NXP4VVNnW0GQR1XS
EW-1 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLyN4NKSzVyPUKuNVchdk1? MXjTRW5ITVJ?
KS-1 NXLSSVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon0TWM2OD1{LkS1JI5O MnPIV2FPT0WU
SK-LMS-1 NWrXZ2lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwNEmgcm0> NGGxfo9USU6JRWK=
TGBC1TKB M37GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDGTWM2OD1{Lk[5JI5O MXfTRW5ITVJ?
TE-6 NIL0Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj3WFF5UUN3ME2yMlc4KG6P MmLOV2FPT0WU
ETK-1 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi0WFZKSzVyPUKuPFIhdk1? MlfFV2FPT0WU
BE-13 M3zN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwOUmgcm0> NVSyU3NmW0GQR1XS
A3-KAW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GwUGlEPTB;Mj65PUBvVQ>? MXfTRW5ITVJ?
TE-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H5SmlEPTB;Mz6zJI5O NEnWeGtUSU6JRWK=
DOHH-2 NGDqRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[yRpNZUUN3ME2zMlM2KG6P MVTTRW5ITVJ?
ES6 M1j0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XvV2lEPTB;Mz60N{BvVQ>? NXHvTYltW0GQR1XS
OPM-2 NGWxfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwMUWgcm0> MWLTRW5ITVJ?
SH-4 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDpTWM2OD12LkO0JI5O NIjMZpdUSU6JRWK=
NB13 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\MeWFMUUN3ME20MlM3KG6P M3LQcnNCVkeHUh?=
HUTU-80 M{e5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjoTWM2OD12LkSyJI5O MYnTRW5ITVJ?
CCRF-CEM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD12Lkm0JI5O MWrTRW5ITVJ?
TGBC24TKB M2riO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIXYxKSzVyPUWuOVEhdk1? MlPpV2FPT0WU
697 NXHHTWh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPzd4FiUUN3ME22MlI5KG6P MnfZV2FPT0WU
J-RT3-T3-5 M{TUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH4TWM2OD14LkS2JI5O MXrTRW5ITVJ?
KALS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33DUmlEPTB;Nj61OkBvVQ>? M1rtWHNCVkeHUh?=
no-10 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdwMkmgcm0> MYjTRW5ITVJ?
SK-NEP-1 M2qwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PUfGlEPTB;OD63PUBvVQ>? M4DSfXNCVkeHUh?=
L-540 M1\0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP3WHNKSzVyPUGwMlQzKG6P NIracllUSU6JRWK=
JiyoyeP-2003 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFyLkm0JI5O NUTwPW4zW0GQR1XS
HH NYrJdXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LkcWlEPTB;MUGuN|khdk1? MnOzV2FPT0WU
SR M4\NTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jJOmlEPTB;MUGuOFUhdk1? M4TKb3NCVkeHUh?=
QIMR-WIL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe4U4xIUUN3ME2xNU45PSCwTR?= NVjvUYhLW0GQR1XS
A4-Fuk M1r4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzRXnNKSzVyPUGzMlEzKG6P NIXrb3FUSU6JRWK=
CESS NIf0XGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCTWM2OD1zMz6xN{BvVQ>? MXvTRW5ITVJ?
KE-37 M4LMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n6NmlEPTB;MU[uNFchdk1? NYXybIRkW0GQR1XS
SK-UT-1 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\hS2lEPTB;MU[uPFEhdk1? NFvsN49USU6JRWK=
SIG-M5 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF5LkK1JI5O M3Pzb3NCVkeHUh?=
HT NYLqd3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF34O5hKSzVyPUG3MlYhdk1? MkWwV2FPT0WU
DEL MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF5Lkm5JI5O MXrTRW5ITVJ?
SK-PN-DW M4DXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJyLkKzJI5O NIjz[|BUSU6JRWK=
RPMI-8402 NEniNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rjdWlEPTB;MkGuO|chdk1? M3[5cXNCVkeHUh?=
RPMI-6666 NILGeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPKTnd3UUN3ME2yOE41OiCwTR?= M{\2[HNCVkeHUh?=
NCI-H720 M2HnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ3LkSxJI5O NX;6elRUW0GQR1XS
EW-16 M3zzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ4Lki3JI5O NHTGZphUSU6JRWK=
BL-70 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3lRWh4UUN3ME2yPE4{QCCwTR?= NWX4d204W0GQR1XS
SF126 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojKTWM2OD1|MD6zPEBvVQ>? MUDTRW5ITVJ?
BC-1 NUHpdXZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHRV4ZKSzVyPUOxMlI3KG6P NVe0XVBFW0GQR1XS
MHH-PREB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DZYZKSzVyPUOyMlQ1KG6P MV7TRW5ITVJ?
A101D MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qz[2lEPTB;M{KuOlIhdk1? M1PETnNCVkeHUh?=
NMC-G1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzuNVdKSzVyPUOzMlY4KG6P MVrTRW5ITVJ?
LB1047-RCC NFr3VnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS5TWM2OD1|ND62PUBvVQ>? MoDQV2FPT0WU
EM-2 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP0TWM2OD1|OD61N{BvVQ>? NIXneoRUSU6JRWK=
COLO-684 M4PWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN7Lkigcm0> NUnQZY11W0GQR1XS
Becker MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW3TWM2OD12MT6wOUBvVQ>? M3W5T3NCVkeHUh?=
BL-41 NWDoNm03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHUXGR{UUN3ME20N{43PiCwTR?= M1KyTnNCVkeHUh?=
MDA-MB-134-VI MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lTWM2OD12ND6wNkBvVQ>? MXrTRW5ITVJ?
L-363 M4fwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHyUo5VUUN3ME20OE44OyCwTR?= MnfoV2FPT0WU
ECC4 M1\0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\tSoVKSzVyPUS0Mlc5KG6P MUXTRW5ITVJ?
A388 NVnTPZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHJTWM2OD12ND64NkBvVQ>? MUjTRW5ITVJ?
HEL NXn1VYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR7Lke5JI5O Moe1V2FPT0WU
RKO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SzUmlEPTB;NUCuNlkhdk1? MnT0V2FPT0WU
KINGS-1 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS4S2FSUUN3ME21NU42PSCwTR?= NXzsWJdUW0GQR1XS
EB-3 M3;Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfj[ohKSzVyPUWyMlY4KG6P NH[2PItUSU6JRWK=
ARH-77 NH7YRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GXWJyUUN3ME21Nk45KG6P MXHTRW5ITVJ?
GCIY NFnuSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfTZ3FKSzVyPUWzMlQ3KG6P MUXTRW5ITVJ?
NCI-H1304 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonkTWM2OD13Nz6yNkBvVQ>? MX;TRW5ITVJ?
KARPAS-299 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL4TWM2OD14MT64NkBvVQ>? M170UHNCVkeHUh?=
IA-LM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ITWM2OD14OD6xN{BvVQ>? M2q1N3NCVkeHUh?=
GI-1 M4Cx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT1S5hIUUN3ME23NE4{QSCwTR?= NEjRVFhUSU6JRWK=
TE-11 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\STWM2OD15Nz6xO{BvVQ>? NIPXbGhUSU6JRWK=
LS-411N M3X0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjBTWM2OD15Nz61O{BvVQ>? NYn6[Ih7W0GQR1XS
no-11 NYnKR5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnDSmJuUUN3ME24N{4zPCCwTR?= MYPTRW5ITVJ?
MV-4-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\UTWM2OD16Mz63N{BvVQ>? M1uxNnNCVkeHUh?=
BV-173 NGrEVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMTWM2OD16Mz65O{BvVQ>? MlXqV2FPT0WU
CMK NXrGVHE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K5[GlEPTB;OESuNVYhdk1? NUjYNpVUW0GQR1XS
LC4-1 NVO4UGx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP4TWM2OD16Nj63NkBvVQ>? MVfTRW5ITVJ?
COR-L279 NVLMSm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj2[|BKSzVyPUi3MlI2KG6P MUnTRW5ITVJ?
NCI-H209 M3zJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vzOmlEPTB;OEeuOFEhdk1? MXrTRW5ITVJ?
Raji NWH5NVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuyZndRUUN3ME24PU44OiCwTR?= NETxWJdUSU6JRWK=
LB996-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjTPXNsUUN3ME25N{41OyCwTR?= MWrTRW5ITVJ?
NCI-H526 NHjrTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LOemlEPTB;OUOuOVkhdk1? MkTKV2FPT0WU
KGN Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHxTWM2OD17Nj6yPUBvVQ>? NVnxT5dUW0GQR1XS
MOLT-4 M2XKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTSZ|BKSzVyPUm2Mlc6KG6P MYfTRW5ITVJ?
PF-382 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\1b2lEPTB;OU[uO|khdk1? MoHFV2FPT0WU
BC-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvWbW1KSzVyPUm5MlE5KG6P M1L5e3NCVkeHUh?=
KARPAS-422 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj1TWM2OD1zMEKuNFkhdk1? NY\sOohPW0GQR1XS
SBC-1 NV\iSpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\5bolKSzVyPUGwO{44PSCwTR?= M{[w[HNCVkeHUh?=
LC-1F NF65NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HxZ2lEPTB;MUC4MlA2KG6P Ml7PV2FPT0WU
GB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DUO2lEPTB;MUC5MlAzKG6P MYPTRW5ITVJ?
SNB75 NH;5bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDFTWM2OD1zMUmuOlkhdk1? MkS4V2FPT0WU
BB65-RCC M3GzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\6bY5KSzVyPUGxPU46OyCwTR?= M4nxTnNCVkeHUh?=
NCI-N87 NEW2NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPsTWM2OD1zMkGuPVghdk1? MULTRW5ITVJ?
IST-MEL1 NUL6OJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjMRYhzUUN3ME2xNlIvOzhibl2= MlnXV2FPT0WU
HOP-62 M{CwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvKTWM2OD1zMk[uPFkhdk1? Mni2V2FPT0WU
ACN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml60TWM2OD1zNE[uO|Uhdk1? MUTTRW5ITVJ?
DMS-114 M2fDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF3MD62O{BvVQ>? MVvTRW5ITVJ?
MLMA M4fTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7GU4ZrUUN3ME2xOVkvQDhibl2= M3y2ZnNCVkeHUh?=
HT-144 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nw[WlEPTB;MU[1MlQ{KG6P MXrTRW5ITVJ?
C2BBe1 M4nNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXPTWM2OD1zNkeuO|Yhdk1? MnnrV2FPT0WU
L-428 NVfkeFN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWThU4pQUUN3ME2xO|cvPyCwTR?= MlfqV2FPT0WU
DU-4475 NHy2c49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF6Nz62PEBvVQ>? MkjOV2FPT0WU
CP67-MEL NFOweoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;CUmhKUUN3ME2xPVkvOzhibl2= NFf0To1USU6JRWK=
MEG-01 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJyMT65OkBvVQ>? NV\KemJ4W0GQR1XS
IST-SL2 NIO5VpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJyOD62N{BvVQ>? MXnTRW5ITVJ?
ES8 NFTzXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGroVVJKSzVyPUKyOU46PCCwTR?= MlLHV2FPT0WU
COLO-800 NGTFOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnrTWM2OD1{M{WuNlghdk1? MmnJV2FPT0WU
MFH-ino NXHkXZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLo[4FCUUN3ME2yN|UvQDRibl2= MlP4V2FPT0WU
OVCAR-4 NULXXnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrqfnNKSzVyPUKzO{4zPCCwTR?= M2XlOHNCVkeHUh?=
PSN1 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\Ic|B5UUN3ME2yOFIvPzFibl2= MUfTRW5ITVJ?
EW-12 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ2Mz6xJI5O NX;XUWxIW0GQR1XS
HCC1599 NHXnfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ4MT60O{BvVQ>? M2XCTnNCVkeHUh?=
SJSA-1 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDCfIZoUUN3ME2yO|EvPDZibl2= M33qRnNCVkeHUh?=
ST486 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZbGlEPTB;Mkm2MlE1KG6P MXjTRW5ITVJ?
NOMO-1 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGwTWM2OD1|MECuNlEhdk1? MmHvV2FPT0WU
MN-60 NXvE[WxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnQfIdKSzVyPUOwOU4{OiCwTR?= MUXTRW5ITVJ?
HCC1187 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;qU|A4UUN3ME2zNFcvOjVibl2= M{mx[3NCVkeHUh?=
SW982 NVHoUnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD1|MUSuO|Uhdk1? NXXiNldCW0GQR1XS
LB647-SCLC NFvOdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTqTVNKSzVyPUOyPE44OSCwTR?= MmGwV2FPT0WU
HC-1 NYnFb21TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHHZ4pKSzVyPUOzOU42KG6P NF;yfJBUSU6JRWK=
EHEB M1L1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnfGNKSzVyPUOzO{42OiCwTR?= MmH1V2FPT0WU
TUR MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN4Mz65OUBvVQ>? MWXTRW5ITVJ?
LU-139 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGxTVRxUUN3ME2zO|gvODJibl2= MYHTRW5ITVJ?
NB1 NWW0eYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v1UWlEPTB;M{i0MlQ2KG6P M4\afXNCVkeHUh?=
BB30-HNC MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO2TWM2OD1|OEiuN|Ihdk1? MmnaV2FPT0WU
HAL-01 M{TIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPxTWM2OD1|OEmuNlYhdk1? Mo\aV2FPT0WU
K5 NFrOXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiwTWM2OD12MUGuN|chdk1? NIj1dVBUSU6JRWK=
MZ2-MEL M{LBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfOTWM2OD12MUOuOlQhdk1? Mk\HV2FPT0WU
RXF393 NGfjW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTRzNj60OUBvVQ>? M4\ib3NCVkeHUh?=
NCI-H1648 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRzNz61N{BvVQ>? M2LuTnNCVkeHUh?=
TE-12 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q2dGlEPTB;NEO0MlI3KG6P MYjTRW5ITVJ?
EoL-1- MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr1OZh2UUN3ME20N|cvQThibl2= MmrCV2FPT0WU
JAR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz1bGZkUUN3ME20N|gvPjJibl2= NHvMXFBUSU6JRWK=
DSH1 NWTZelc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR3OD65NUBvVQ>? NV36b5BXW0GQR1XS
NCI-H187 M2O1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR4Mj64NUBvVQ>? NFLPT|NUSU6JRWK=
HCE-4 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGxXHVKSzVyPUS3O{43PiCwTR?= MUfTRW5ITVJ?
8-MG-BA NGrZXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX3OWtKSzVyPUW4NU42OiCwTR?= MmW0V2FPT0WU
KLE MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYPJF[UUN3ME21PFUvOiCwTR?= M1HZVnNCVkeHUh?=
KNS-42 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHpVpExUUN3ME21PFYvQDFibl2= MlTjV2FPT0WU
MSTO-211H NV\kdmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTuTWM2OD14MEmuO|Qhdk1? MV7TRW5ITVJ?
GDM-1 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTZzND6wPUBvVQ>? MXXTRW5ITVJ?
TE-1 M{PwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m4dWlEPTB;NkS2MlEzKG6P MX7TRW5ITVJ?
BT-474 NHzlRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXTTHdKSzVyPU[0O{4xPiCwTR?= NHvSUGNUSU6JRWK=
KARPAS-45 NIPJPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPJWY1KSzVyPU[0O{43KG6P NV32Snh2W0GQR1XS
MOLT-16 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZ2Nz65N{BvVQ>? NULIZpRHW0GQR1XS
KURAMOCHI NEPiOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWyfnA4UUN3ME22OVcvPTFibl2= MofiV2FPT0WU
K-562 NX7aUIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfIe5RkUUN3ME22OlkvPTFibl2= MkT6V2FPT0WU
EKVX M{\hXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC0WVU5UUN3ME22O|IvPzFibl2= NGLGRXBUSU6JRWK=
GAK M37TXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZ5NT6zJI5O MnrrV2FPT0WU
NCI-SNU-5 NEnYTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\zTWM2OD14OUCuNFEhdk1? M2\5NHNCVkeHUh?=
NCI-H2126 M1fWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHThVnNKSzVyPUeyOk45PyCwTR?= M1n1NnNCVkeHUh?=
CTV-1 NUPPWHloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTd2ND65JI5O NGLCUVRUSU6JRWK=
SW962 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT4OXd[UUN3ME23OFgvPDRibl2= MWTTRW5ITVJ?
MONO-MAC-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjERnBKSzVyPUe1Ok46OyCwTR?= NF35V2RUSU6JRWK=
NCI-H748 NGLpNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3RV|hKSzVyPUe1PE46QSCwTR?= MXfTRW5ITVJ?
NCI-H524 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;TTWM2OD15OECuO|Mhdk1? MXzTRW5ITVJ?
LS-123 NVPyVZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTd7NT62PUBvVQ>? M4\0cXNCVkeHUh?=
NB7 NEHKSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37xVmlEPTB;OEG0MlE1KG6P MYLTRW5ITVJ?
LS-1034 NUTrOZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnZ[nVKSzVyPUiyPE46QCCwTR?= MWPTRW5ITVJ?
TE-5 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTh6Mz61OkBvVQ>? MmjkV2FPT0WU
A704 M1TqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjr[29KSzVyPUi5PU4yPSCwTR?= MVXTRW5ITVJ?
TK10 M1LRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnDNHNKSzVyPUmxOk4xOyCwTR?= MV;TRW5ITVJ?
NCI-H345 NXjOPWZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PtcGlEPTB;OUSzMlIzKG6P NV;1UnJ5W0GQR1XS
CGTH-W-1 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rFSGlEPTB;OUS4MlE{KG6P NW\nWnQ1W0GQR1XS
NCI-H510A NEjM[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTl6NT6xNkBvVQ>? NF7mXmZUSU6JRWK=
NCI-H1963 M3fXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrycGpKSzVyPUGuNFMzQTJizszN MX\TRW5ITVJ?
SCC-3 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\zTWM2OD1zLkCzOFE1KM7:TR?= M37KVHNCVkeHUh?=
EW-11 M3O5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPFbGNKSzVyPUGuNFg4PDNizszN MWjTRW5ITVJ?
CPC-N MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T1cmlEPTB;MT6wPFgh|ryP NYLZU3dzW0GQR1XS
NCI-H1417 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\wOopKSzVyPUGuNVIzPiEQvF2= NXz5epZHW0GQR1XS
DG-75 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwMU[yPFUh|ryP MmG3V2FPT0WU
HD-MY-Z M3;VbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXsWVhKSzVyPUGuNVY1OTZizszN NEDN[4hUSU6JRWK=
ATN-1 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXBTWM2OD1zLkK2NlA6KM7:TR?= M4f3T3NCVkeHUh?=
KM-H2 M4r4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOxc5VKSzVyPUGuNlY1ODhizszN NILKTWlUSU6JRWK=
NCI-H2081 NYDWTIxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rORmlEPTB;MT6yOlY{PyEQvF2= NHz0WWRUSU6JRWK=
HL-60 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjPXXZTUUN3ME2xMlI3QTV7IN88US=> M17ZN3NCVkeHUh?=
DB NH\uOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO2cWk{UUN3ME2xMlI4OjR{IN88US=> NXzRVHF2W0GQR1XS
NCI-H1522 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljxTWM2OD1zLkK4PFg4KM7:TR?= NHfTemxUSU6JRWK=
AM-38 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwM{C3NkDPxE1? MnjNV2FPT0WU
NCI-H446 NGjyOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nPN2lEPTB;MT6zNlEzOSEQvF2= M4KxXnNCVkeHUh?=
SU-DHL-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwM{K4NFEh|ryP MnHuV2FPT0WU
NH-12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zhSWlEPTB;MT6zOlM4PCEQvF2= M3;Y[XNCVkeHUh?=
DMS-79 NVH2dlhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;JclJKSzVyPUGuN|Y5PjZizszN NEPLeXBUSU6JRWK=
NCI-H716 NXziXYZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwM{i5PFYh|ryP NHyxb|BUSU6JRWK=
ML-2 NF74NJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13FUmlEPTB;MT60NVUzQSEQvF2= MXvTRW5ITVJ?
NB10 NUT0VXBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPDTWM2OD1zLkS2OlMzKM7:TR?= NWnHZXZuW0GQR1XS
ONS-76 M3LCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO3TWM2OD1zLkWzOVY6KM7:TR?= MXLTRW5ITVJ?
LOUCY Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\TbYNKSzVyPUGuOVQ3PTdizszN MkTrV2FPT0WU
SCLC-21H NIDkbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwNUi1PFIh|ryP MoHLV2FPT0WU
TGW MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS4OZJDUUN3ME2xMlY{QTd3IN88US=> NELuRoFUSU6JRWK=
LXF-289 M1XRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP0fmN[UUN3ME2xMlc{OjZ6IN88US=> NXWxNXpqW0GQR1XS
BB49-HNC NGHaNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP0V2JKSzVyPUGuO|M2QDZizszN NEjjRYtUSU6JRWK=
NCI-H747 NE\SVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwN{WzOFYh|ryP NGfYWYRUSU6JRWK=
LU-165 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzreY5KSzVyPUGuPFQ6QDZizszN M4qwXXNCVkeHUh?=
OMC-1 NX3uZoFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETjOplKSzVyPUGuPVUxPjZizszN NF3WSlRUSU6JRWK=
RCC10RGB MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PSZ2lEPTB;MT65OVgyPyEQvF2= M4HmbnNCVkeHUh?=
SW684 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO0TWM2OD1zLkm2NFk6KM7:TR?= NV;qfXlPW0GQR1XS
TE-8 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXobYtKSzVyPUKuNFU2PTlizszN NHfwVWdUSU6JRWK=
SK-N-DZ NEHDNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnjTWM2OD1{LkGzNlc1KM7:TR?= M1LnfnNCVkeHUh?=
EVSA-T NYrpXm9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvNYNQUUN3ME2yMlE4OzF3IN88US=> M3zlNXNCVkeHUh?=
KASUMI-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nPeWlEPTB;Mj6xPFgyPSEQvF2= MV\TRW5ITVJ?
NKM-1 NInYOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjeVUyUUN3ME2yMlI2PDd{IN88US=> NHv0e4JUSU6JRWK=
CAL-148 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrqSHRzUUN3ME2yMlM{PjF2IN88US=> NX3aXGxCW0GQR1XS
NCI-H64 M4fnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe4W4RqUUN3ME2yMlM1OjN{IN88US=> MYLTRW5ITVJ?
KNS-81-FD NXTmfHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULPb|FIUUN3ME2yMlM3PjJizszN MlPpV2FPT0WU
KM12 NXr4UYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS4TWM2OD1{LkSwPFM6KM7:TR?= MlHoV2FPT0WU
SW954 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne4TWM2OD1{LkS3O|c6KM7:TR?= MWXTRW5ITVJ?
NCI-H1395 NGrDfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvDTWM2OD1{LkWyOlQ2KM7:TR?= NITnOZZUSU6JRWK=
DJM-1 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDRTZpRUUN3ME2yMlYxPjNizszN NHnJSIFUSU6JRWK=
COLO-668 NFTYfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJwOEK2PVUh|ryP MkPmV2FPT0WU
NCI-H1436 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjlZllKSzVyPUKuPFU3OTVizszN NX:2bFFNW0GQR1XS
LB2241-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTpTWM2OD1{Lki2PFM6KM7:TR?= NFTnOWFUSU6JRWK=
GT3TKB MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLwN2tjUUN3ME2yMlg6ODV3IN88US=> MUPTRW5ITVJ?
COLO-824 NIjBS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF64dIdKSzVyPUKuPFk4PjhizszN MnLDV2FPT0WU
ES1 NEjUXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuxPG85UUN3ME2yMlg6QDd7IN88US=> MWDTRW5ITVJ?
LB771-HNC M{jUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwOUC5OFYh|ryP NXnQTo83W0GQR1XS
GI-ME-N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwMEC5NFQh|ryP NVnIT4NMW0GQR1XS
NALM-6 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\GeWlEPTB;Mz6wNFk{OyEQvF2= MVrTRW5ITVJ?
LU-134-A M4X1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XifGlEPTB;Mz6wOVQzPSEQvF2= NUDZfIk2W0GQR1XS
DMS-153 NX3jc5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwMEW4NlQh|ryP M3X6bHNCVkeHUh?=
MZ1-PC MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwMEmwO|gh|ryP NV;6PVdTW0GQR1XS
NCI-H1155 NVHMV|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n1TWlEPTB;Mz6xNVYyKM7:TR?= NGDCWpBUSU6JRWK=
CAS-1 M1rVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;W[WlEPTB;Mz6xN|cxPyEQvF2= MlH5V2FPT0WU
D-502MG NEjJcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO2eJQxUUN3ME2zMlE1OzlizszN MWPTRW5ITVJ?
NCI-H2141 NH;iUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TWZmlEPTB;Mz6xO|Q2OiEQvF2= MmXBV2FPT0WU
NB6 M{LUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwMUiyOVkh|ryP NY\yUY5GW0GQR1XS
NCCIT Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtTWM2OD1|LkKxPFA6KM7:TR?= MUDTRW5ITVJ?
NB69 M{HGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjiS41KSzVyPUOuN|E5QTFizszN MmjlV2FPT0WU
JVM-2 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPrT2p4UUN3ME2zMlM3PDN|IN88US=> MkOzV2FPT0WU
K052 NU\2cXV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULvSoxMUUN3ME2zMlM4QTZ6IN88US=> M2TlZXNCVkeHUh?=
HCC2157 NHq4e45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3npZ2lEPTB;Mz61N|IzQCEQvF2= NWmwb|A1W0GQR1XS
KMOE-2 M13Tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KzU2lEPTB;Mz61OFI1OiEQvF2= Ml:xV2FPT0WU
SF268 M4L1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DBN2lEPTB;Mz63NVU2PCEQvF2= NYrkd2E5W0GQR1XS
CHP-126 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDMR4I6UUN3ME2zMlc3PDV6IN88US=> NID4[JRUSU6JRWK=
CP66-MEL NVLMVFZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvPTWM2OD1|Lke5NFk1KM7:TR?= NIPnV3RUSU6JRWK=
NCI-H69 NF7EcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMEG5N|Yh|ryP Mn7uV2FPT0WU
A253 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXWZ4pKSzVyPUSuNFIyODFizszN M1XOcXNCVkeHUh?=
NB14 NWnsbGJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHSTWM2OD12LkGwOFc6KM7:TR?= M3q0UHNCVkeHUh?=
NCI-H1694 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TZOGlEPTB;ND6xN|EyOiEQvF2= NE\mWZFUSU6JRWK=
NCI-H2196 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr5cppqUUN3ME20MlE4OTZ7IN88US=> NH3EU5VUSU6JRWK=
TE-9 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzSTWM2OD12LkG3OVgzKM7:TR?= M1ezOHNCVkeHUh?=
D-283MED MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnhTWM2OD12LkG4PFQh|ryP Ml\JV2FPT0WU
OCI-AML2 NX3ifItVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrZeWxKSzVyPUSuNVk1QDlizszN MUXTRW5ITVJ?
D-263MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwMkK5OlEh|ryP MoLoV2FPT0WU
MPP-89 NVGwNJUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnrXXJnUUN3ME20MlI4OzB2IN88US=> NVixbmc{W0GQR1XS
LAMA-84 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnVS5BGUUN3ME20MlMxPDJzIN88US=> NHHsXW5USU6JRWK=
LB373-MEL-D NYfjWpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LmSmlEPTB;ND6zOlc5QSEQvF2= MWnTRW5ITVJ?
UACC-257 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwM{m1N|Qh|ryP M{HVfnNCVkeHUh?=
MC-CAR MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD12LkSzPVkh|ryP NYPTdGRWW0GQR1XS
COLO-320-HSR MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwNES0Nlch|ryP NX;iXIZbW0GQR1XS
P30-OHK MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfvbolpUUN3ME20MlY3PThzIN88US=> NHj5VJNUSU6JRWK=
UACC-812 NF\iRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW2TWM2OD12Lk[5NVYyKM7:TR?= MWDTRW5ITVJ?
CTB-1 NEfVW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\qWWlEPTB;ND63NVU2PSEQvF2= M2XRTXNCVkeHUh?=
ALL-PO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwOESwO|ch|ryP MnzNV2FPT0WU
SK-MEL-2 NGWxRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj3bZFKSzVyPUSuPFY6PTVizszN MoTYV2FPT0WU
TC-YIK MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfYeFhKSzVyPUSuPVc6PDJizszN NEDGW2VUSU6JRWK=
NCI-H1882 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;DTWM2OD13LkCyNFAyKM7:TR?= M4T3eHNCVkeHUh?=
MHH-CALL-2 NF;oXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:0bo46UUN3ME21MlA2ODR{IN88US=> NEPrXndUSU6JRWK=
U-87-MG M3jyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiyVW1KSzVyPUWuNFk1PjZizszN MVvTRW5ITVJ?
NCI-H1092 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjzeJBDUUN3ME21MlI3PTV3IN88US=> MUPTRW5ITVJ?
TE-441-T NVT4N5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTxSJNYUUN3ME21MlI4QDJizszN MYrTRW5ITVJ?
SK-MEL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTNe29SUUN3ME21MlI6ODR2IN88US=> NFzsUmpUSU6JRWK=
EW-22 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK2VIpNUUN3ME21MlI6PDZ4IN88US=> MoDoV2FPT0WU
MZ7-mel MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPIXYN4UUN3ME21MlQxPjlzIN88US=> NXHPVG1PW0GQR1XS
LP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPBcJpKSzVyPUWuOFEzQTFizszN NHO1O49USU6JRWK=
NCI-SNU-16 M2\hfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD13Lk[0NFc1KM7:TR?= MWDTRW5ITVJ?
LU-65 M3LPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTVwN{[zO|Mh|ryP M{LQ[XNCVkeHUh?=
CW-2 M4XMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vXbGlEPTB;NT64OVk2QSEQvF2= NVS4cFFTW0GQR1XS
WSU-NHL M4T4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37XOWlEPTB;NT65OVE4PCEQvF2= MljBV2FPT0WU
IST-MES1 NVHxWlhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7VdI5KSzVyPUWuPVU1PDNizszN MXzTRW5ITVJ?
U-266 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7WVIRKSzVyPUWuPVgzODJizszN MY\TRW5ITVJ?
TALL-1 NVrpW5RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zE[2lEPTB;Nj6xOFY5QCEQvF2= M4LhdXNCVkeHUh?=
Calu-6 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZwMUWzNVYh|ryP M1ewRnNCVkeHUh?=
MMAC-SF NFTObpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS0[IFmUUN3ME22MlE5PTV4IN88US=> NF;TSZVUSU6JRWK=
NCI-H82 NYrkNmxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M323[2lEPTB;Nj6yNFQ5QSEQvF2= MVfTRW5ITVJ?
RS4-11 NYjDUWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK0[2NKSzVyPU[uNlU5QTdizszN MmqxV2FPT0WU
SNU-C2B Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;qNWlEPTB;Nj60NFk3QSEQvF2= M1jLTnNCVkeHUh?=
BOKU NEHzWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\aUWlEPTB;Nj60O|U6PyEQvF2= MlT1V2FPT0WU
C8166 M4rRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXvcpJrUUN3ME22MlU2QTF{IN88US=> NHnQWo9USU6JRWK=
D-247MG M1fJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXneWdKSzVyPUeuNFQ{PDdizszN MnX5V2FPT0WU
EW-18 M2LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvOTWM2OD15LkC3NlkzKM7:TR?= NV:w[Yw1W0GQR1XS
KG-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjpc|lsUUN3ME23MlYzPzN6IN88US=> MXnTRW5ITVJ?
REH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqTWM2OD15Lk[4NVA6KM7:TR?= M{nvdnNCVkeHUh?=
U-698-M MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLhUJdKSzVyPUeuPFQ{OTVizszN Mn3lV2FPT0WU
KP-N-RT-BM-1 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnaTWM2OD15LkmzNFI6KM7:TR?= NY[xcIR2W0GQR1XS
MS-1 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPZWlEPTB;Nz65OlA1OSEQvF2= NYH3Zo5JW0GQR1XS
SNU-C1 NFHuVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTdwOUixPVIh|ryP M3vyeHNCVkeHUh?=
SK-MM-2 NXHqVmZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRThwMk[wOlUh|ryP NX:2WYZPW0GQR1XS
LAN-6 NGfnW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kPHlKSzVyPUiuN|AxODFizszN MWTTRW5ITVJ?
NEC8 NE\wbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DicmlEPTB;OD6zNFY6OSEQvF2= MofyV2FPT0WU
NCI-H1770 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfsSYVFUUN3ME24MlM5ODB{IN88US=> M13tWXNCVkeHUh?=
D-336MG NHTV[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTac4lXUUN3ME24MlQxOTF4IN88US=> MUXTRW5ITVJ?
COLO-829 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvIV29vUUN3ME24MlQ5QDd7IN88US=> Mk\jV2FPT0WU
LS-513 NV[yT5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQbFZIUUN3ME24MlU6PTl7IN88US=> NGTLTXRUSU6JRWK=
YT MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTPU3Z1UUN3ME24MlYzPDJ5IN88US=> NI[3TlRUSU6JRWK=
EW-24 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr1XodoUUN3ME24Mlc3PTRizszN M4HBO3NCVkeHUh?=
IST-SL1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRThwOE[1OFMh|ryP NWLyUYN1W0GQR1XS
CA46 NILZVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRThwOUWwPVgh|ryP NG\HWFRUSU6JRWK=
NCI-H1838 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRThwOUi2NFIh|ryP MUDTRW5ITVJ?
NCI-H719 M4my[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwMkWyO|kh|ryP MlzQV2FPT0WU
HCE-T NVzldpQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LUOWlEPTB;OT6zNFg2OSEQvF2= Mn3oV2FPT0WU
A498 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KxS2lEPTB;OT6zOlEzPCEQvF2= M3\yZ3NCVkeHUh?=
LB831-BLC M3jSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTlwN{[1NlEh|ryP MWjTRW5ITVJ?
SKM-1 NV:2T3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLm[YROUUN3ME25Mlg2QTZ|IN88US=> NYm2R5MzW0GQR1XS
THP-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljvTWM2OD17Lkm2PVE5KM7:TR?= NU[3W5JCW0GQR1XS
SHP-77 NF:0e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD3TWM2OD1zMD60NFch|ryP NYLQdXVRW0GQR1XS
EW-3 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTDSJJYUUN3ME2xNE43Ojh7IN88US=> NHnmZYlUSU6JRWK=
KY821 M{DXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\5dGlEPTB;MUCuO|Y{KM7:TR?= MUPTRW5ITVJ?
NCI-SNU-1 NYPsT25pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFzLkCyNVch|ryP NVj5R24zW0GQR1XS
HCC2218 NXfxSHZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPPOXdiUUN3ME2xNU4{QTh4IN88US=> NV;j[oNNW0GQR1XS
IM-9 M2nGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFzLkWxNFYh|ryP NVLXNVJRW0GQR1XS
NCI-H889 M1jtc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LjWGlEPTB;MUGuOVMyOyEQvF2= MU\TRW5ITVJ?
HDLM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nPd2lEPTB;MUKuOFE2QSEQvF2= NIfzOlZUSU6JRWK=
LB2518-MEL MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq4TWM2OD1zMj62PFE2KM7:TR?= NGHvTJlUSU6JRWK=
NCI-H23 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkK0NlUh|ryP M{W0OnNCVkeHUh?=
NB17 NYLzelV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ntUWlEPTB;MUOuOFU4QSEQvF2= M2L2bXNCVkeHUh?=
NCI-H322M MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF2LkSwOlgh|ryP NVnOfIJjW0GQR1XS
SUP-T1 M{\CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;vPWpOUUN3ME2xOE41OTNizszN MYXTRW5ITVJ?
ES3 NHq5cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTNTWM2OD1zNT6wO|A{KM7:TR?= NIrTdGpUSU6JRWK=
ES5 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImxRotKSzVyPUG1MlA4QDdizszN MofNV2FPT0WU
NCI-H1650 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF3LkS5O|kh|ryP MoH3V2FPT0WU
NCI-H226 NV7BTFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7nTWM2OD1zNT64O|Y5KM7:TR?= Ml7FV2FPT0WU
COR-L88 NUj2UFZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXXTWM2OD1zNj6zNVQh|ryP MlXVV2FPT0WU
SCC-15 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF4LkO4Olkh|ryP MkD1V2FPT0WU
GOTO NV;iOpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[0TWM2OD1zNj60O|k{KM7:TR?= M2XTbHNCVkeHUh?=
SIMA M2DFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPWPJpKSzVyPUG2MlQ5ODJizszN MnjpV2FPT0WU
NCI-H1299 NHjDXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn6bolvUUN3ME2xO{4yPTlzIN88US=> Mn\VV2FPT0WU
NCI-H1581 M{Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLYTWM2OD1zNz60NlE6KM7:TR?= MVfTRW5ITVJ?
MHH-NB-11 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fpT2lEPTB;MUeuPVY5OyEQvF2= MnLiV2FPT0WU
MFM-223 NH2wbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF6LkC1N|gh|ryP MX;TRW5ITVJ?
ES7 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\CVWxKSzVyPUG4MlU1OzFizszN MU\TRW5ITVJ?
JVM-3 NF[5PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6LkexO{DPxE1? MUHTRW5ITVJ?
RL NWPUfmp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;tXo9KSzVyPUKwMlM5QCEQvF2= MnfJV2FPT0WU
EC-GI-10 NXzBRnM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHDTXlxUUN3ME2yNU4zODRzIN88US=> MXrTRW5ITVJ?
LNCaP-Clone-FGC M3LkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjFTWM2OD1{MT62O|Y5KM7:TR?= MorEV2FPT0WU
IMR-5 NEHZNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5TWM2OD1{MT64OFk1KM7:TR?= M{jjVnNCVkeHUh?=
KP-N-YS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHDcXhKSzVyPUKxMlg4PSEQvF2= MXrTRW5ITVJ?
Mo-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrZbnNKSzVyPUKyMlIyQDVizszN NXToPW91W0GQR1XS
NCI-H128 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ|LkW4OVMh|ryP MWPTRW5ITVJ?
RH-1 NUDSPXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ|Lke4OlYh|ryP MYLTRW5ITVJ?
NCI-H2171 NE\3bJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TkSGlEPTB;MkSuNlQ5PSEQvF2= MW\TRW5ITVJ?
RPMI-8866 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfsTWM2OD1{Nj63OFIh|ryP MVTTRW5ITVJ?
SK-N-FI MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ5LkO4NVEh|ryP NHezOVRUSU6JRWK=
LOXIMVI M3XnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\6UmlEPTB;MkeuPFA2OSEQvF2= NE\wNHdUSU6JRWK=
P31-FUJ NWPmSXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKwTWM2OD1|MT61N|c1KM7:TR?= MnHMV2FPT0WU
KMS-12-PE NYXIXVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzNTWM2OD12OT61N|AzKM7:TR?= MkjFV2FPT0WU

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]
- Collapse

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]
- Collapse
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]
- Collapse
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13
CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989，NSC-2260804
Smiles COC1CC(CCC1O)CC(C)C2CC(=O)C(C)\C=C(/C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C(C)/C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N4CCCCC4C(=O)O2)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04172922 Not yet recruiting Drug: Topical Sirolimus Vascular Anomaly Nemours Children''s Clinic December 1 2019 Phase 1
NCT04128722 Active not recruiting Drug: Sirolimus Oral Liquid Product 1mg/mL Lingual Microcystic Lymphatic Malformations University Hospital Tours November 30 2019 Phase 2
NCT03433183 Active not recruiting Drug: Selumetinib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT04348292 Recruiting Drug: Durvalumab|Drug: Sirolimus Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8 Emory University|National Cancer Institute (NCI) October 22 2019 Phase 1
NCT03933904 Active not recruiting Drug: Sirolimus Castleman Disease|Castleman''s Disease Multicentric University of Pennsylvania September 25 2019 Phase 2
NCT03972592 Recruiting Drug: Topical 0.1% Sirolimus|Drug: Topical Vehicle Vascular Malformations|Lymphatic Malformation University Hospital Tours|University Hospital Angers June 5 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

Antineoplastic and Immunosuppressive Antibiotics Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID